MASI
Masimo Corporation
NASDAQ: MASI · HEALTHCARE · MEDICAL DEVICES
$178.50
-0.04% today
Updated 2026-06-05
Market cap
$9.42B
P/E ratio
44.43
P/S ratio
6.05x
EPS (TTM)
$4.05
Dividend yield
—
52W range
$5 – $180
Volume
0.8M
WallStSmart proprietary scores
56
out of 100
Grade: C+
Hold
Investment rating
6.0
Growth
B8.0
Quality
A6.5
Profitability
B4.0
Valuation
C6/9
Piotroski F-Score
Moderate
3.4
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$180.00
+0.84%
12-Month target
—
—
Intrinsic (DCF)
$141.85
Margin of safety
+4.80%
0 Strong Buy0 Buy8 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Altman Z 3.43 — safe zone
+ Free cash flow $40.00M — positive
Risks
- Thin margins at 4.90%
- P/E 44.43x — expensive valuation
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $2.04B | $2.05B | $2.09B | $1.53B | $1.56B |
| Net income | $143.50M | $81.50M | $-304.90M | $-151.50M | $57.10M |
| EPS | — | — | — | — | $4.05 |
| Free cash flow | $-26.90M | $6.40M | $145.30M | $198.40M | $40.00M |
| Profit margin | 7.05% | 3.98% | -14.56% | -9.92% | 4.90% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-29 | SCANNELL, TIMOTHY J | Sale | 1,225 | — |
| 2026-04-29 | SCANNELL, TIMOTHY J | Buy | 1,225 | — |
| 2026-04-29 | LANE, WENDY E | Sale | 1,225 | — |
Peer comparison
Smart narrative
Masimo Corporation trades at $178.50. representing a P/E of 44.43x trailing earnings. Our Smart Value Score of 56/100 indicates the stock is fair. The company scores 6/9 on the Piotroski F-Score. With an Altman Z-Score of 3.43, it sits in the safe zone. TTM revenue stands at $1.56B. with profit margins at 4.90%. Our DCF model estimates intrinsic value at $141.85.
Frequently asked questions
What is Masimo Corporation's stock price?
Masimo Corporation (MASI) trades at $178.50, on a P/E of 44.4x and a P/S of 6.1x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Masimo Corporation overvalued?
Masimo Corporation carries a Smart Value Score of 56/100 (Grade C+), which we rate Hold. That score blends growth, quality, and valuation into one read. Our DCF puts intrinsic value at $141.85 versus the $178.50 price, a 4.8% margin of safety on a cash flow basis.
What is the price target of Masimo Corporation (MASI)?
The 12-month analyst consensus target is $180.00, about 0.8% above the current $178.50. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the intrinsic value of Masimo Corporation (MASI)?
Our DCF model estimates intrinsic value at $141.85, a +4.8% margin of safety versus today's $178.50. Intrinsic value is what the projected cash flows are worth today. A positive reading means the price sits below that estimate, leaving a cushion if growth holds.
What is Masimo Corporation's revenue?
Masimo Corporation's trailing twelve-month revenue is $1.56B. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Masimo Corporation's Altman Z-Score is 3.43, which places it in the safe zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryMEDICAL DEVICES
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio6.05x
ROE9.67%
Beta1.10
50D MA$178.60
200D MA$156.05
Shares out0.05B
Float0.04B
Short ratio—
Avg volume0.8M
Performance
1 week-0.75%
1 month+1.00%
3 months+35.38%
YTD+36.18%
1 year—
3 years—
5 years—